{"id":3899,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/daunorubicin-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"daunorubicin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/daunorubicin-txt\/","title":{"rendered":"Daunorubicin.txt"},"content":{"rendered":"

Daunorubicin<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:Acute leukaemias

DOSE IN NORMAL RENAL FUNCTION <\/H3>30\u201345 mg\/m2, or as for local protocol

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :564 (as hydrochloride)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :50\u201390<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 5\u201318<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :39.2<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :18.5; Liposomal: 4\u20135.2\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Reconstitute 20 mg vial with 4 mL water for injection giving a concentration of 5 mg\/mL. Dilute calculated dose of daunorubicin further in sodium chloride 0.9% to give a final concentration of 1 mg\/mL

    Route <\/H4>IV

    Rate of Administration <\/H4>1 mg\/mL solution should be infused over 20 minutes into the tubing or a side arm of a rapidly flowing

    IV infusion <\/H4> of sodium chloride 0.9%

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Potentially cardiotoxic Monitor blood uric acid and urea levels Rapidly taken up by the tissues, especially by the kidneys, liver, spleen and heart. Subsequent release of drug and metabolites is slow (T\u00bd ~55 hrs). Rapidly metabolised in the liver, and the major metabolite daunorubicinol is also active. It is excreted slowly in the urine, mainly as metabolites with 25% excreted within 5 days. Biliary excretion accounts for 40\u201350% eliminationManufacturer\u2019s literature suggests that in patients with a serum creatinine of 105\u2013265 \u00b5mol\/L the dose should be reduced to 75% of normal; if the creatinine is >265 \u00b5mol\/L, the dose should be 50% of normalA liposomal formulation of daunorubicin is now available (DaunoXome ). Dilute to 0.2\u20131 mg\/mL with glucose 5% and administer over 30\u201360 minutes
    \n","protected":false},"excerpt":{"rendered":"

    Daunorubicin CLINICAL USE Antineoplastic agent:Acute leukaemias DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3899","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3899"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3899\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}